Klaus Hager

from Wikipedia, the free encyclopedia

Klaus Hager (born June 23, 1955 in Selb ) is a German gerontologist and geriatrician , professor and former medical director of the Diakoniekrankenhaus Henriettenstiftung in Hanover. He is known for his work in the field of gerontology and geriatrics, especially dementia and Alzheimer's disease .

Life

Hager studied human medicine at the University of Erlangen-Nuremberg and the University of Rennes I from 1976 to 1983 . He was licensed as a doctor in 1983 and received his doctorate in 1984. In 1990 he was certified as a specialist in internal medicine and in 1996 for physical and rehabilitation medicine. Since 1992 he has been chief physician at the Center for Old Age Medicine at the Diakovere Hospital in Hanover. He is a specialist in internal medicine and a specialist in physical and rehabilitation medicine. Other training titles: rescue medicine, physical therapy, psychotherapy, medical quality management, geriatrics. Since 1995 there has been an authorization to hold a memorial consultation in Hanover. This has been recommended in Focus since 2012 as a contact point for Alzheimer's disease. www. During his clinical work, he is an expert for courts, public prosecutors and arbitration boards in Germany. In addition to his clinical work at the Medical Clinic II of the City Clinic in Nuremberg from 1983 to 1992, he was a research assistant at the Institute for Gerontology, Chair of Internal Medicine / Gerontology at the University of Erlangen-Nuremberg. In 1992 he received his habilitation in internal medicine and experimental gerontology at the University of Erlangen-Nuremberg. In 1995 he received a rehabilitation at the Medical University of Hanover combined with the acquisition of a teaching qualification in internal medicine and gerontology as a private lecturer. In 2000, Hager was appointed Associate Professor at the Hannover Medical School. Since 2004 he has been organizing student teaching for the cross-sectional subject Q7 (Medicine of Aging and the Elderly), and has been teaching since 2009. From 1997 to 2006 he was medical director and board member of the Henrietten Foundation , and from 2006 to 2012 medical director of the Diakoniekrankenhaus Henrietten Foundation. Since 2016 he has been the spokesman for the State Association of Geriatrics in Lower Saxony.

Scientific contribution

The publications include work on changes in coagulation in old age, dementia, geriatric rehabilitation and palliative medicine. Laboratory work and clinical geriatric topics are dealt with equally. Since 1995, a large area has been participating in international multicenter studies to test drugs against dementia, in particular against Alzheimer's dementia, as a so-called Principal Investigator of the Study Center (PI) or, in more than 10 studies, as the national head of clinical trials (LKP) or as a "national coordinator".

Memberships in scientific associations

  • Gerontological Society of America (GSA)
  • American Geriatrics Society (AGS)
  • Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART)
  • Swiss Geriatric Society (SFGG-SPSG)
  • Austrian Geriatric Society (ÖGGG)
  • Section I (Biology of Aging) of the German Society for Gerontology and Geriatrics (DGGG)
  • German Society for Geriatrics (DGG)
  • German Society for Aging Research (DGfA)
  • Geriatrics section of the BDI
  • German Society for Internal Medicine
  • 2002–2008 President of the German Society for Aging Research
  • 2002–2003 Past-President of the German Society for Geriatrics

Publications

List of publications

Selected scientific articles

  • RW Jones, H. Soininen, K. Hager, D. Aarsland, P. Passmore, A. Murthy, R. Zhang, R. Bahra: A multinational, randomized, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. In: Int J Geriatr Psychiatry. 19 (1), 2004, pp. 58-67.
  • N. Ahmed, U. Ahmed, PJ Thornalley, K. Hager, G. Fleischer, G. Münch: Protein glycation, oxidation and nitration marker residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. In: J. Neurochem. 92/2, 2005, pp. 255-263.
  • L. Holmquist, G. Stuchbury, K. Berbaum, S. Muscat, S. Young, K. Hager, J. Engel, G. Münch: Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. In: Pharmacol Ther. 113/1, 2007, pp. 154-164.
  • A. Maczurek, K. Hager, M. Kenklies, M. Sharman, R. Martins, J. Engel, DA Carlson, G. Münch: Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. In: Advanced Drug Delivery Reviews. 60, 2008, pp. 1463-1470.
  • K. Hager, AS Baseman, JS Nye, HR Brashear, J. Han, M. Sano, B. Davis, HM Richards: Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. In: Neuropsychiatric Disease and Treatment. 10, 2014, pp. 391–401, PMC 3937252 (free full text)
  • K. Hager, M. Brecht, O. Krause, V. Grosse: Influence of cognition on treatment results in geriatrics - connection between MMSE and gain in everyday activities. In: Journal of Gerontology and Geriatrics. 47/5, 2014, pp. 379–384.
  • K. Klindtworth, P. Oster, K. Hager, O. Krause, J. Bleidorn, N. Schneider: Living with and dying from advanced heart failure: understanding the needs of elderly patients at the end of life. In: BMC Geriatrics. 15, 2015, pp. 125-136, PMC 4608315 (free full text)
  • K. Hager, AS Baseman, JS Nye, HR Brashear, J. Han, M. Sano, B. Davis, HM Richards: Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: Post hoc analysis of a randomized placebo-controlled study. In: Alzheimer's Research & Therapy. 8, 2016, pp. 47-57. ( online )

Web links

Individual evidence

  1. THE CENTER FOR MEDICINE IN AGING
  2. THE MEMORY CONSULTATION IN THE HENRIETTENSTIFT
  3. Geriatrie.de
  4. ^ German Society for Aging Research